Develops medicines designed to carry large molecules across the blood-brain barrier for people with neurodegenerative, lysosomal storage and other serious diseases.
10-K for FY2025, filed Feb 26, 2026Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering…View ↗
Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous…View ↗
We are building a broad portfolio of therapeutic candidates by investing in our TV franchises, i.e., Enzyme TV ("ETV"), Oligonucleotide TV…View ↗
Denali collaborates with biopharmaceutical companies and other research partners to develop and commercialize candidates. For approved candidates, it plans to sell in key markets itself and/or use partners or distributors.
10-K for FY2025, filed Feb 26, 2026
10-Q for Q3 FY2026, filed Nov 3, 2026
$70.1MView ↗
8-K, filed Aug 6, 2026
In its first full quarter of commercial availability, AVLAYAH generated $3.6 million in net product revenue. Projected third-quarter 2026…View ↗
8-K, filed Apr 3, 2026
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its…View ↗
From plans to launch preparation
The older report described internal manufacturing and commercial infrastructure as capabilities to build in stages; the latest says a clinical manufacturing facility is open and commercial readiness is in place for tividenofusp alfa.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 26, 2026
Competes with Biogen, Eisai, Eli Lilly, Arrowhead, Roche, AbbVie, Bristol Myers Squibb, Prothena, Regeneron, Alnylam, BioArctic, Ionis, AstraZeneca, Takeda, Neuron23, Passage Bio, AviadoBio, Vesperbio, Arkuda Therapeutics, and Orchard Therapeutics
10-K for FY2025, filed Feb 26, 2026Alzheimer’s Disease: Treatments currently approved in some geographies for Alzheimer’s Disease include the amyloid beta-directed antibody…View ↗
Loading...